Skip to main content
Premium Trial:

Request an Annual Quote

Young-Ki Paik, Rolf Apweiler, Pierre LeGrain, Gil Ommen, Catherine Costello, Richard Simpson, Dennis Hochstrasser, Matthias Mann, Gerhard Muller, James Hawkins, Bethany Mancilla, Douglas Swirsky, Andrew Armstrong, Adam Feldman

Young-Ki Paik was elected the new president of the Human Proteome Organization this week, replacing Rolf Apweiler. Paik will begin his two-year term in January 2009. Paik is director of the Yonsei Proteome Research in Seoul, South Korea.
Also, Pierre LeGrain was elected new secretary of HUPO. He is director of life sciences at the French Commissariat à l’Energie Atomique. Gil Omen was elected vice president. He is a professor of internal medicine, human genetics, and public health at the University of Michigan and leads HUPO’s Human Plasma Proteome Project. Catherine Costello will become the new senior vice president. She is director of the Boston University School of Medicine, Mass Spectrometry Resource.

Richard Simpson, Dennis Hochstrasser, Matthias Mann, and Costello were given awards by HUPO this week in recognition of their contributions to proteomics.
Simpson, a professor at the Ludwig Institute for Cancer Research, was given the HUPO Distinguished Service Award for “indispensible contributions in his service to HUPO since the inauguration of HUPO in 2000,” the organization said, adding he “has demonstrated extraordinary commitment to the education and training of scientists in proteomic sciences.”
Hochstrasser, chairman of the Genetics and Laboratory Medicine department and head of Laboratory Medicine service at Geneva University Hospital, shared HUPO’s Distinguished Achievement Award in Proteomics with Mann.
HUPO noted Hochstrasser’s innovative work in “the methodology of two-dimensional electrophoresis and mass spectrometry and his perception for the need for the integration of the methodology with electronic data processing, [which] have contributed decisively to the techniques becoming one of the main protein separation methods used in proteomics.”
Mann, a director of the Max-Planck Institute of Biochemistry, developed a number of instrumental advances in mass spectrometry and the first bioinformatic search algorithm for peptide fragment data, HUPO said.
And Costello was given the HUPO Discovery in Proteomic Services award for her contributions “to the structural elucidation of glycolipids and lipids and of post-translational modifications that are involved in the onset and progress of infectious and parasitic diseases, protein misfolding, disorders, and cardiovascular disease,” HUPO said.

Proteros Biostructures announced Gerhard Muller has been appointed chief scientific officer and managing director of the newly founded subsidiary Proteros Fragments. He will be responsible for the design and expansion of the company’s in-house compound and fragment library, the fragment evolutionary process and the transition into lead optimization. In that context, he will work closely with Mercachem, Proteros’s chemistry partner in the joint offering regarding structure-based lead generation.
Muller was most recently vice president of drug discovery at GPC Biotech. He has also worked at GlaxoSmithKline, Bayer, and NV Organon.

James Hawkins, Bethany Mancilla, and Douglas Swirsky have been named to the business advisory board of Calibrant Biosystems.

Andrew Armstrong and Adam Feldman were among 19 winners of the Young Investigators Awards awarded by the Prostate Cancer Foundation for 2008. Each winner will receive $75,000 annually for three years for their research.
Armstrong, a physician at Duke University, will focus on biomarker discovery for the identification of patients at higher risk for aggressive clinical progression of prostate cancer.
Feldman, a doctor at the Massachusetts General Hospital Cancer Center, is doing research into novel biomarkers in urine. His work also seeks to correlate new biomarkers discovered with diagnosis, grade, and pathologic stage.

The Scan

CDC Calls Delta "Variant of Concern"

CNN reports the US Centers for Disease Control and Prevention now considers the Delta variant of SARS-CoV-2 to be a "variant of concern."

From FDA to Venture Capital

Former FDA Commissioner Stephen Hahn is taking a position at a venture capital firm, leading some ethicists to raise eyebrows, according to the Washington Post.

Consent Questions

Nature News writes that there are questions whether informed consent was obtained for some submissions to a database of Y-chromosome profiles.

Cell Studies on Multimodal Single-Cell Analysis, Coronaviruses in Bats, Urban Microbiomes

In Cell this week: approach to analyze multimodal single-cell genomic data, analysis of bat coronaviruses, and more.